"Angiotensin II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
| Descriptor ID |
D000804
|
| MeSH Number(s) |
D06.472.699.094.078 D12.644.400.070.078 D12.644.456.073.041 D12.644.548.058.078 D12.776.631.650.070.078 D23.469.050.050.050
|
| Concept/Terms |
Angiotensin II- Angiotensin II
- ANG-(1-8)Octapeptide
- Angiotensin-(1-8) Octapeptide
Angiotensin II, Ile(5)-- Angiotensin II, Ile(5)-
- Angiotensin II, Isoleucine(5)-
- 5-L-Isoleucine Angiotensin II
- 5 L Isoleucine Angiotensin II
- Angiotensin II, 5-L-Isoleucine
- Isoleucine(5)-Angiotensin
- Isoleucyl(5)-Angiotensin II
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II".
This graph shows the total number of publications written about "Angiotensin II" by people in this website by year, and whether "Angiotensin II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 2 | 2 | 4 |
| 1996 | 5 | 4 | 9 |
| 1997 | 3 | 1 | 4 |
| 1998 | 6 | 1 | 7 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 4 | 5 |
| 2001 | 2 | 1 | 3 |
| 2002 | 3 | 0 | 3 |
| 2003 | 3 | 7 | 10 |
| 2004 | 3 | 3 | 6 |
| 2005 | 1 | 2 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 4 | 5 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 4 | 6 |
| 2011 | 4 | 2 | 6 |
| 2012 | 2 | 1 | 3 |
| 2013 | 4 | 1 | 5 |
| 2014 | 3 | 3 | 6 |
| 2015 | 0 | 5 | 5 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 3 | 3 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin II" by people in Profiles.
-
Systemic delivery of targeted nanotherapeutic reverses angiotensin II-induced abdominal aortic aneurysms in mice. Sci Rep. 2021 04 21; 11(1):8584.
-
Sepsis 2019: What Surgeons Need to Know. Surg Infect (Larchmt). 2020 Apr; 21(3):195-204.
-
Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition. BMB Rep. 2019 Oct; 52(10):595-600.
-
Critical role of the endogenous renin-angiotensin system in maintaining self-renewal and regeneration potential of epidermal stem cells. Biochim Biophys Acta Mol Basis Dis. 2019 10 01; 1865(10):2647-2656.
-
Suppression of angiotensin II-induced pathological changes in heart and kidney by the caveolin-1 scaffolding domain peptide. PLoS One. 2018; 13(12):e0207844.
-
Angiotensin II and the Natriuretic and Blood Pressure Response to Mental Stress in African Americans. Ethn Dis. 2018; 28(4):511-516.
-
A NOX4/TRPC6 Pathway in Podocyte Calcium Regulation and Renal Damage in Diabetic Kidney Disease. J Am Soc Nephrol. 2018 07; 29(7):1917-1927.
-
Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3?/Fyn pathway. Redox Biol. 2018 05; 15:405-417.
-
Nitric oxide production by glomerular podocytes. Nitric Oxide. 2018 01 30; 72:24-31.
-
Elevated Wall Tension Initiates Interleukin-6 Expression and Abdominal Aortic Dilation. Ann Vasc Surg. 2018 Jan; 46:193-204.